Cargando…

On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer

BACKGROUND: Inflammation is a factor that promotes tumor progression and immunosuppression. Lung immune prognostic index (LIPI) is a non-invasive and easily calculated indicator of inflammation. This study aimed to investigate whether continuous assessment of LIPI has predictive value for chemoimmun...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Anning, Xu, Jianlin, Wang, Shuyuan, Zhong, Runbo, Lu, Jun, Chu, Tianqing, Zhang, Wei, Li, Ying, Zheng, Xiaoxuan, Han, Baohui, Nie, Wei, Zhong, Hua, Zhang, Xueyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247997/
https://www.ncbi.nlm.nih.gov/pubmed/37304273
http://dx.doi.org/10.3389/fimmu.2023.1173025
_version_ 1785055274143318016
author Xiong, Anning
Xu, Jianlin
Wang, Shuyuan
Zhong, Runbo
Lu, Jun
Chu, Tianqing
Zhang, Wei
Li, Ying
Zheng, Xiaoxuan
Han, Baohui
Nie, Wei
Zhong, Hua
Zhang, Xueyan
author_facet Xiong, Anning
Xu, Jianlin
Wang, Shuyuan
Zhong, Runbo
Lu, Jun
Chu, Tianqing
Zhang, Wei
Li, Ying
Zheng, Xiaoxuan
Han, Baohui
Nie, Wei
Zhong, Hua
Zhang, Xueyan
author_sort Xiong, Anning
collection PubMed
description BACKGROUND: Inflammation is a factor that promotes tumor progression and immunosuppression. Lung immune prognostic index (LIPI) is a non-invasive and easily calculated indicator of inflammation. This study aimed to investigate whether continuous assessment of LIPI has predictive value for chemoimmunotherapy in non-small cell lung cancer (NSCLC) patients receiving first-line programmed cell death 1 (PD-1) inhibitor plus chemotherapy. In addition, the predictive value of LIPI in patients with the negative or low programmed death-ligand (PD-L1) expression level was also explored. METHODS: Totally, 146 stage IIIB to IV or recurrent NSCLC patients who received first-line PD-1 inhibitor combined with chemotherapy were enrolled in this study. The LIPI scores were calculated at baseline (PRE-LIPI) and after two cycles of the combined administration (POST-LIPI). This study analyzed the relationship between good/intermediate/poor PRE (POST)-LIPI and objective response rate (ORR), as well as progression-free survival (PFS) using logistic and Cox regression models. In addition, the predictive value of LIPI in patients with the negative or low PD-L1 expression level was explored. To further assess the potential predictive value of continuous assessment of LIPI, the association of sum (LIPI) [sum(LIPI) = PRE-LIPI + POST-LIPI] and PFS was analyzed in the 146 patients. RESULTS: Compared with good POST-LIPI group, significantly lower ORRs were found in intermediate POST-LIPI (P = 0.005) and poor POST-LIPI (P = 0.018) groups. Moreover, intermediate POST-LIPI (P =0.003) and poor POST-LIPI (P < 0.001) were significantly associated with a shorter PFS than good POST-LIPI. Additionally, a higher POST-LIPI score was still significantly associated with poorer treatment efficacy in patients with the negative or low PD-L1 expression level. Moreover, a higher sum (LIPI) score was significantly correlated with a shorter PFS (P = 0.001). CONCLUSION: Continuous assessment of LIPI might be an effective method for predicting the efficacy of PD-1 inhibitor plus chemotherapy in NSCLC patients. In addition, in patients with the negative or low PD-L1 expression level, it might also have a potential predictive value for therapeutic efficacy to continuously assess LIPI during the treatment.
format Online
Article
Text
id pubmed-10247997
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102479972023-06-09 On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer Xiong, Anning Xu, Jianlin Wang, Shuyuan Zhong, Runbo Lu, Jun Chu, Tianqing Zhang, Wei Li, Ying Zheng, Xiaoxuan Han, Baohui Nie, Wei Zhong, Hua Zhang, Xueyan Front Immunol Immunology BACKGROUND: Inflammation is a factor that promotes tumor progression and immunosuppression. Lung immune prognostic index (LIPI) is a non-invasive and easily calculated indicator of inflammation. This study aimed to investigate whether continuous assessment of LIPI has predictive value for chemoimmunotherapy in non-small cell lung cancer (NSCLC) patients receiving first-line programmed cell death 1 (PD-1) inhibitor plus chemotherapy. In addition, the predictive value of LIPI in patients with the negative or low programmed death-ligand (PD-L1) expression level was also explored. METHODS: Totally, 146 stage IIIB to IV or recurrent NSCLC patients who received first-line PD-1 inhibitor combined with chemotherapy were enrolled in this study. The LIPI scores were calculated at baseline (PRE-LIPI) and after two cycles of the combined administration (POST-LIPI). This study analyzed the relationship between good/intermediate/poor PRE (POST)-LIPI and objective response rate (ORR), as well as progression-free survival (PFS) using logistic and Cox regression models. In addition, the predictive value of LIPI in patients with the negative or low PD-L1 expression level was explored. To further assess the potential predictive value of continuous assessment of LIPI, the association of sum (LIPI) [sum(LIPI) = PRE-LIPI + POST-LIPI] and PFS was analyzed in the 146 patients. RESULTS: Compared with good POST-LIPI group, significantly lower ORRs were found in intermediate POST-LIPI (P = 0.005) and poor POST-LIPI (P = 0.018) groups. Moreover, intermediate POST-LIPI (P =0.003) and poor POST-LIPI (P < 0.001) were significantly associated with a shorter PFS than good POST-LIPI. Additionally, a higher POST-LIPI score was still significantly associated with poorer treatment efficacy in patients with the negative or low PD-L1 expression level. Moreover, a higher sum (LIPI) score was significantly correlated with a shorter PFS (P = 0.001). CONCLUSION: Continuous assessment of LIPI might be an effective method for predicting the efficacy of PD-1 inhibitor plus chemotherapy in NSCLC patients. In addition, in patients with the negative or low PD-L1 expression level, it might also have a potential predictive value for therapeutic efficacy to continuously assess LIPI during the treatment. Frontiers Media S.A. 2023-05-25 /pmc/articles/PMC10247997/ /pubmed/37304273 http://dx.doi.org/10.3389/fimmu.2023.1173025 Text en Copyright © 2023 Xiong, Xu, Wang, Zhong, Lu, Chu, Zhang, Li, Zheng, Han, Nie, Zhong and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Xiong, Anning
Xu, Jianlin
Wang, Shuyuan
Zhong, Runbo
Lu, Jun
Chu, Tianqing
Zhang, Wei
Li, Ying
Zheng, Xiaoxuan
Han, Baohui
Nie, Wei
Zhong, Hua
Zhang, Xueyan
On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer
title On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer
title_full On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer
title_fullStr On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer
title_full_unstemmed On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer
title_short On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer
title_sort on-treatment lung immune prognostic index is predictive for first-line pd-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247997/
https://www.ncbi.nlm.nih.gov/pubmed/37304273
http://dx.doi.org/10.3389/fimmu.2023.1173025
work_keys_str_mv AT xionganning ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer
AT xujianlin ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer
AT wangshuyuan ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer
AT zhongrunbo ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer
AT lujun ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer
AT chutianqing ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer
AT zhangwei ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer
AT liying ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer
AT zhengxiaoxuan ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer
AT hanbaohui ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer
AT niewei ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer
AT zhonghua ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer
AT zhangxueyan ontreatmentlungimmuneprognosticindexispredictiveforfirstlinepd1inhibitorcombinedwithchemotherapyinpatientswithnonsmallcelllungcancer